Prion disease: Review of the literature.
Keywords:
Neurological deterioration, Prions, Clinical manifestations, EncephalitisAbstract
Prion disease are entities of unknown genetic origin that cause in human beings a number of neurological manifestations that lead patients to states of immobility and severe deterioration, with a very poor prognosis and uncertain cure rates. It is difficult to find in the literature important findings to determine the clinical diagnosis and pharmacological methodology to counteract the deterioration of patients suffering from this condition. Therefore, a systematic search was carried out in the PubMed database. Research from 1990 to 2020 that addressed the diagnostic criteria of Creutzfeldt-Jackobs disease in adults, its clinical manifestations, diagnosis and management, recommendations and management guidelines were included to demonstrate the situation of patients who present this type of alterations and deterioration neurological diagnosis of difficult diagnosis, to determine clinical criteria that can give a clinical orientation for the diagnosis of these entities.
Downloads
References
Kühlmann I. Entdeckungsreise. 2020.
Krasnianski A, Schulz-Schaeffer WJ, Kallenberg K, et al. Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. Brain. 2006;129(9):2288-2296. DOI: 10.1093/brain/awl123
Villar-Piqué A, Schmitz M, Candelise N, Ventura S, Llorens F, Zerr I. Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases. Mol Neurobiol. 2018;55(9):7588-7605. DOI: 10.1007/s12035-018-0926-y
Kraus A, Saijo E, Metrick MA, et al. Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease. Acta Neuropathol. 2019;137(4):585-598. DOI: 10.1007/s00401-018-1947-3
Monreal J, Collins GH, Masters CL, et al. Elsevier / North-Holland Biomedical Press C R E U T Z F E L D T - J A K O B DISEASE IN A N A D O L E S C E N T SUMMARY A 16-year-old boy was stricken with a progressive neurologic disorder char- acterized primarily by dementia progressing to severe neurol. 1981:341-350.
Ladogana A, Puopolo M, Croes EA, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005;64(9):1586-1591. DOI: 10.1212/01.WNL.0000160117.56690.B2
Verity C, Winstone AM, Will R, et al. Surveillance for variant CJD: Should more children with neurodegenerative diseases have autopsies? Arch Dis Child. 2019;104(4):360-365. DOI: 10.1136/archdischild-2018-315458
Lasmézas CI, Fournier JG, Nouvel V, et al. Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob Disease: Implications for human health. Proc Natl Acad Sci U S A. 2001;98(7):4142-4147. DOI: 10.1073/pnas.041490898
Llewelyn CA, Hewitt PE, Knight RSG, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363(9407):417-421. DOI: 10.1016/S0140-6736(04)15486-X
Moda F, Bolognesi ML, Legname G. Novel screening approaches for human prion diseases drug discovery. Expert Opin Drug Discov. 2019;14(10):983-993. DOI: 10.1080/17460441.2019.1637851
Morales R, Duran-Aniotz C, Diaz-Espinoza R, Camacho M V., Soto C. Protein misfolding cyclic amplification of infectious prions. Nat Protoc. 2012;7(7):1397-1409. DOI: 10.1038/nprot.2012.067
Giaccone G, Moda F. Pmca applications for prion detection in peripheral tissues of patients with variant creutzfeldt-jakob disease. Biomolecules. 2020;10(3). DOI: 10.3390/biom10030405
Bélondrade M, Jas-Duval C, Nicot S, et al. Correlation between Bioassay and Protein Misfolding Cyclic Amplification for Variant Creutzfeldt-Jakob Disease Decontamination Studies. mSphere. 2020;5(1):1-11. DOI: 10.1128/msphere.00649-19
Murayama Y, Yoshioka M, Okada H, Takata M, Yokoyama T, Mohri S. Urinary excretion and blood level of prions in scrapie-infected hamsters. J Gen Virol. 2007;88(10):2890-2898. DOI: 10.1099/vir.0.82786-0
Krance SH, Luke R, Shenouda M, et al. Cellular Models for Discovering Prion Disease Therapeutics: Progress and Challenges. Vol 153.; 2020. DOI: 10.1111/jnc.14956
Orrú CD, Bongianni M, Tonoli G, et al. A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med. 2014;371(6):519-529. DOI: 10.1056/NEJMoa1315200
Notari S, Moleres FJ, Hunter SB, et al. Multiorgan detection and characterization of protease-resistant prion protein in a case of variant CJD examined in the United States. PLoS One. 2010;5(1). DOI: 10.1371/journal.pone.0008765
Parchi P, De Boni L, Saverioni D, et al. Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: An inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol. 2012;124(4):517-529. DOI: 10.1007/s00401-012-1002-8
Masters CL, Harris JO, Gajdusek DC, Gibbs CJ, Bernoulli C, Asher DM. Creutzfeldt‐Jakob disease: Patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol. 1979;5(2):177-188. DOI: 10.1002/ana.410050212
Peden AH, Head MW, Ritchie DL, Bell PJE, Ironside PJW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364(9433):527-529. DOI: 10.1016/S0140-6736(04)16811-6
Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95(23):13363-13383. DOI: 10.1073/pnas.95.23.13363
Rösler TW, Tayaranian Marvian A, Brendel M, et al. Four-repeat tauopathies. Prog Neurobiol. 2019;180(May):101644. DOI: 10.1016/j.pneurobio.2019.101644
Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P. Sporadic human prion diseases: Molecular insights and diagnosis. Lancet Neurol. 2012;11(7):618-628. DOI: 10.1016/S1474-4422(12)70063-7
Rossi M, Baiardi S, Parchi P. Understanding prion strains: Evidence from studies of the disease forms affecting humans. Viruses. 2019;11(4):1-27. DOI: 10.3390/v11040309
Bishop M, Hart P, Aitchison L, et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol. 2006;5(5):393-398. DOI: 10.1016/S1474-4422(06)70413-6
Camacho M V., Telling G, Kong Q, Gambetti P, Notari S. Role of prion protein glycosylation in replication of human prions by protein misfolding cyclic amplification. Lab Investig. 2019;99(11):1741-1748. DOI: 10.1038/s41374-019-0282-1
Bougard D, Bélondrade M, Mayran C, et al. Diagnosis of methionine/valine variant creutzfeldt-jakob disease by protein misfolding cyclic amplification. Emerg Infect Dis. 2018;24(7):1364-1366. DOI: 10.3201/eid2407.172105
Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21(10):1332-1340. DOI: 10.1038/s41593-018-0235-9
Lyon A, Mays CE, Borriello F, Telling GC, Soto C, Pritzkow S. Application of PMCA to screen for prion infection in a human cell line used to produce biological therapeutics. Sci Rep. 2019;9(1):1-6. DOI: 10.1038/s41598-019-41055-x
Saa P. Reports 8. 2005;1071(2004):2004-2007.
Brandner S, Whitfield J, Boone K, et al. Central and peripheral pathology of kuru: Pathological analysis of a recent case and comparison with other forms of human prion disease. Philos Trans R Soc B Biol Sci. 2008;363(1510):3755-3763. DOI: 10.1098/rstb.2008.0091
Saá P, Castilla J, Soto C. Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J Biol Chem. 2006;281(46):35245-35252. DOI: 10.1074/jbc.M603964200
Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. 2001;411(6839):810-813. DOI: 10.1038/35081095
Johnson RT, Gonzalez RG, Frosch MP. Case 27-2005: An 80-year-old man with fatigue, unsteady gait, and confusion. N Engl J Med. 2005;353(10):1042-1050. DOI: 10.1056/NEJMcpc059024
Saijo E, Metrick MA, Koga S, et al. Correction to: 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration (Acta Neuropathologica, (2020), 139, 1, (63-77), 10.1007/s00401-019-02080-2). Acta Neuropathol. 2020;139(1):79-81. DOI: 10.1007/s00401-019-02092-y
Seeger H, Heikenwalder M, Zeller N, et al. Medicine: Coincident scrapie infection and nephritis lead to urinary prion excretion. Science (80- ). 2005;310(5746):324-326. DOI: 10.1126/science.1118829
Silveira JR, Raymond GJ, Hughson AG, et al. The most infectious prion protein particles. Nature. 2005;437(7056):257-261. DOI: 10.1038/nature03989
Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology. 2000;55(8):1075-1081. DOI: 10.1212/WNL.55.8.1075
De Sousa PA, Ritchie D, Green A, Chandran S, Knight R, Head MW. Renewed assessment of the risk of emergent advanced cell therapies to transmit neuroproteinopathies. Acta Neuropathol. 2019;137(3):363-377. DOI: 10.1007/s00401-018-1941-9
Castilla J, Saá P, Soto C. Detection of prions in blood. Nat Med. 2005;11(9):982-985. DOI: 10.1038/nm1286
Tee BL, Longoria Ibarrola EM, Geschwind MD. Prion Diseases. Neurol Clin. 2018;36(4):865-897. DOI: 10.1016/j.ncl.2018.07.005
Thompson AGB, Mead SH. Review: Fluid biomarkers in the human prion diseases. Mol Cell Neurosci. 2019;97:81-92. DOI: 10.1016/j.mcn.2018.12.003
Tixador P, Herzog L, Reine F, et al. The physical relationship between infectivity and prion protein aggregates is strain-dependent. PLoS Pathog. 2010;6(4):1-12. DOI: 10.1371/journal.ppat.1000859
Caughey B, Baron GS, Chesebro B, Jeffrey M. Getting a Grip on Prions: Oligomers, Amyloids, and Pathological Membrane Interactions. Annu Rev Biochem. 2009;78(1):177-204. DOI: 10.1146/annurev.biochem.78.082907.145410
Vanni S, Colini Baldeschi A, Zattoni M, Legname G. Brain aging: A Ianus-faced player between health and neurodegeneration. J Neurosci Res. 2020;98(2):299-311. DOI: 10.1002/jnr.24379
Silva R De, Findlay C, Awad I, Harries- R, Knight R, Will R. Medicine in the elderly Creutzfeldt-Jakob disease in the elderly. 1997;559:557-559.
Vorberg I, Chiesa R. Experimental models to study prion disease pathogenesis and identify potential therapeutic compounds. Curr Opin Pharmacol. 2019;44:28-38. DOI: 10.1016/j.coph.2019.02.002
Zaman M, Khan AN, Wahiduzzaman, Zakariya SM, Khan RH. Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation. Int J Biol Macromol. 2019;134:1022-1037. DOI: 10.1016/j.ijbiomac.2019.05.109
Concha-Marambio L, Chacon MA, Soto C. Preclinical detection of prions in blood of nonhuman primates infected with variant creutzfeldt-jakob disease. Emerg Infect Dis. 2020;26(1):34-43. DOI: 10.3201/eid2601.181423
Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(10):2659-2668. DOI: 10.1093/brain/awp191
Ferreira C, Caughey B. P ro teopa t h i c Seed Amplification Assays for N eurodegen er at i ve D isord e rs. 2020:59840.
Forloni G, Roiter I, Tagliavini F. Clinical trials of prion disease therapeutics. Curr Opin Pharmacol. 2019;44:53-60. DOI: 10.1016/j.coph.2019.04.019
Noel Gill O, Spencer Y, Richard-Loendt A, et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: Large scale survey. BMJ. 2013;347(7929). DOI: 10.1136/bmj.f5675
Gonzalez-Romero D, Barria MA, Leon P, Morales R, Soto C. Detection of infectious prions in urine. FEBS Lett. 2008;582(21-22):3161-3166. DOI: 10.1016/j.febslet.2008.08.003
Gregori L, Kovacs GG, Alexeeva I, Budka H, Rohwer RG. Excretion of transmissible spongiform encephalopathy infectivity in urine. Emerg Infect Dis. 2008;14(9):1406-1412. DOI: 10.3201/eid1409.080259
Head MW, Ritchie D, Smith N, et al. Peripheral Tissue Involvement in Sporadic, Iatrogenic, and Variant Creutzfeldt-Jakob Disease: An Immunohistochemical, Quantitative, and Biochemical Study. Am J Pathol. 2004;164(1):143-153. DOI: 10.1016/S0002-9440(10)63105-7
Hill AF, Collinge J. Subclinical prion infection. Trends Microbiol. 2003;11(12):578-584. DOI: 10.1016/j.tim.2003.10.007
Chatelain J, Cathala F, Brown P, Raharison S, Court L, Gajdusek DC. Epidemiologic comparisons between Creutzfeldt-Jakob disease and scrapie in France during the 12-year period 1968-1979. J Neurol Sci. 1981;51(3):329-337. DOI: 10.1016/0022-510X(81)90111-8
Fang C, Wu B, Le NTT, Imberdis T, Mercer RCC, Harris DA. Prions Activate a P38 MAPK Synaptotoxic Signaling Pathway. Vol 14.; 2018. DOI: 10.1371/journal.ppat.1007283
Kalia L V. Diagnostic biomarkers for Parkinson’s disease: focus on α-synuclein in cerebrospinal fluid. Park Relat Disord. 2019;59:21-25. DOI: 10.1016/j.parkreldis.2018.11.016
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Salutem Scientia Spiritus
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
La Revista Salutem Scientia Spiritus usa la licencia Creative Commons de Atribución – No comercial – Sin derivar: Los textos de la revista son posibles de ser descargados en versión PDF siempre que sea reconocida la autoría y el texto no tenga modificaciones de ningún tipo.
